Cavu Management, LP's Form 4 filing
Lantern Pharma Inc. (LTRN) · filed Jan 19, 2024
- Accession no.
- 0001104659-24-005238
- Filed
- Jan 19, 2024, 4:30 PM ET
- Trade date
- Jan 17, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $247.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cavu Management, LPCIK 0001813270 | 10% Owner |
| Cavu Advisors, LLCCIK 0001813310 | 10% Owner |
| BP Directors, LPCIK 0001813311 | 10% Owner |
| Kreis Leslie W.CIK 0001813316 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 17, 2024 | Common Stock | XIn-the-money exerciseAcquired | +7,347 | $3.13 | +$22,996.11 | 79,121 | Indirect | |
| Jan 17, 2024 | Common Stock | SSaleDisposed | −5,475 | $4.20 | −$22,995 | 73,646 | Indirect | |
| Jan 17, 2024 | Common Stock | XIn-the-money exerciseAcquired | +54,873 | $3.13 | +$171,752.49 | 591,036 | Indirect | |
| Jan 17, 2024 | Common Stock | SSaleDisposed | −40,893 | $4.20 | −$171,750.6 | 550,143 | Indirect | |
| Jan 17, 2024 | Common Stock | XIn-the-money exerciseAcquired | +16,801 | $3.13 | +$52,587.13 | 180,938 | Indirect | |
| Jan 17, 2024 | Common Stock | SSaleDisposed | −12,521 | $4.20 | −$52,588.2 | 168,417 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 17, 2024 | Common Stock | XIn-the-money exerciseDisposed | −7,347 | $0.00 | $0 | 0 | Indirect | |
| Jan 17, 2024 | Common Stock | XIn-the-money exerciseDisposed | −54,873 | $0.00 | $0 | 0 | Indirect | |
| Jan 17, 2024 | Common Stock | XIn-the-money exerciseDisposed | −16,801 | $0.00 | $0 | 0 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.